Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Comparing Two Acute Care Transition Programs for Older Adults and Their Family Caregivers

16 giugno 2026 aggiornato da: Wake Forest University Health Sciences
This study investigates better ways to help people after they leave the hospital and how to involve their families in this process. The main goal is to see if adding family support to a patient-centered hospital-to-home intervention helps patients stay safely at home, spend fewer days back in the emergency room or going back into the hospital. The study team also wants to see if the family-centered approach helps improve the patient's ability to do everyday activities without feeling overwhelmed. Two approaches are being compared: one focuses just on the patient, and the other includes special strategies to better support families involved too. Family will be involved in assessing what the patient and family needs. The family-focused approach not only emphasizes the experience, health, and safety of the patient but also the experience of the family member caring for the older adult. The study also involves families in education and provides families skills-building experiences that can help with caregiving stress, problem-solving, and communicating with the healthcare team. The approach will help the family member prepare for their loved one's transition home and provide coaching with the goal of reducing the mental, physical and financial burden of providing care at home. To spread the intervention across many states, the study team will be using telephone calls, video calls, and other technologies as families prefer.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

For all patients, the transition from hospital to home is a vulnerable period, placing them at great risk for adverse events. In a landmark 2003 report on care transitions, investigators found that 19% of patients experience adverse events soon after discharge (many preventable or ameliorable) and 66% experience adverse drug events. Care transitions also impact those around the recently discharged patient - increasing the burden on family members who provide caregiving support. Without communication and engagement in care transitions, family members experience reduced preparedness for their post-discharge caregiving role, increased caregiver burden, social isolation, and reduced mental/physical well-being.

Patient-centered care transitions can be supported through evidence-based interventions. Recent knowledge generated through PCORI's Transitional Care Evidence to Action Network and other research programs has identified remaining evidence gaps. This Phased Large Award for Comparative Effectiveness Research entitled Comparing Two Acute Care Transition Programs for Older Adults and Their Family Caregivers will create new knowledge related to engaging and supporting family caregivers. After optimization in the feasibility phase, briefly, the Phase 2 comparative effectiveness trial will have the following characteristics:

Setting: 20 Acute Care Hospitals across 5 states selected for rural/urban diversity and patient characteristics Sample: Dyads: Older Adults (N = 1,200) discharged to home and their Family Caregivers (N = 1,200)

Comparators:

Comparator A is an active care transition intervention that includes effective strategies focused on the patient.

Comparator B includes all Comparator A active strategies, plus focused family caregiver engagement and support.

Randomization:

1:1 Dyad-level RCT stratified by rural/urban home setting and presence of patient cognitive impairment

Patient-Centered Outcomes Include: Patient remaining safely at home (60-day hospital free days), post-discharge adverse events, patient-reported outcomes (e.g.: role functioning). Also, this study extends beyond prior effectiveness research by assessing family-caregiver-reported outcomes (e.g.: caregiver burden).

Tipo di studio

Interventistico

Iscrizione (Stimato)

2560

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

  • Stati Uniti
    • North Carolina
      • Bermuda Run, North Carolina, Stati Uniti, 27006
      • High Point, North Carolina, Stati Uniti, 27262
      • North Wilkesboro, North Carolina, Stati Uniti, 28659
      • Winston-Salem, North Carolina, Stati Uniti, 27157

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

Sì

Descrizione

Patient Inclusion Criteria:

  • 65 and older
  • English and Spanish speaking
  • Preadmission location: community dwelling
  • Distance from Hospital: Local and Distant (rural) included
  • Cognitive impairment, dementia allowed
  • Technology Literacy: Flexible from high to low
  • EPIC readmission risk score over 12
  • Discharged home

Patient Exclusion Criteria:

  • Admitted from skilled nursing facility
  • Discharged to skilled nursing facility
  • Left Against Medical Advice (AMA)
  • Planned readmission
  • Died during index admission
  • Caregiver unwilling to participate

Caregiver Inclusion Criteria:

  • Adults 18 and older
  • English and Spanish speaking
  • Providing tangible support to patient
  • Distance from Hospital: Local and Distant (rural) included
  • Only Mild Cognitive Impairment allowed
  • Able to be trained in Video Visit Technology
  • Available to support post-discharge

Caregiver Exclusion Criteria:

• Has a greater than a mild cognitive impairment (≤ 22 on MCA)

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Patient Focused Strategies
An active care transition intervention that includes effective strategies focused on the patient.
Altro: Patient-Centered Intervention
Effective strategies focused on the patient such as patient needs assessment, multi-disciplinary discharge planning, discharge instructions, follow-up education, and follow-up assessments.
Sperimentale: Patient and Family Focused Strategies
An active care transition intervention that includes effective strategies focused on the patient plus focused family caregiver engagement and support.
Altro: Patient-Centered Intervention
Effective strategies focused on the patient such as patient needs assessment, multi-disciplinary discharge planning, discharge instructions, follow-up education, and follow-up assessments.
Altro: Family Caregiver Enhanced Intervention
Caregiver strategies such as a family caregiver needs assessment, structured education, and skill building.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Hospital-Free Days
Lasso di tempo: Day 60
The count of days alive and outside acute care hospitals from discharge to day 60. It will be calculated using EHR and Medicare claims data to objectively capture hospital free days elements (i.e.: mortality days, inpatient days, observation stays, and ED visits).
Day 60

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Hospital-Free Days
Lasso di tempo: Day 30, 90, and 180
The count of days alive and outside acute care hospitals from discharge to a specified day. It will be calculated using EHR and Medicare claims data to objectively capture hospital free days elements (i.e.: mortality days, inpatient days, observation stays, and ED visits).
Day 30, 90, and 180
Number of Patient Readmissions
Lasso di tempo: Day 30, 60, and 90
All-cause, acute care readmissions calculated as both a count and dichotomous using EHR and Medicare claims data.
Day 30, 60, and 90
Zarit Burden Interview Score
Lasso di tempo: Day 60
Caregiver burden will be measured using the 12-item Zarit Burden Interview. Scores will range from 0 to 48. Higher scores indicate greater burden.
Day 60
Zarit Burden Interview Score
Lasso di tempo: Day 30, 90, and 180
Caregiver burden will be measured using the 12-item Zarit Burden Interview. Scores will range from 0 to 48. Higher scores indicate greater burden.
Day 30, 90, and 180
PROMIS Ability to Participate in Social Roles and Activities 8-item short form (APS-SF8) Score
Lasso di tempo: Day 60
Social role function is one's ability to perform usual social roles and activities (e.g.: leisure, family). It will be measured by using the APS-SF8. Each item is scored using a 5-point Likert scale (1=Never, 5=Always). Scores are typically converted to a standardized T-score, with a mean of 50 and a standard deviation of 10.
Day 60
PROMIS Ability to Participate in Social Roles and Activities 8-item short form (APS-SF8) Score
Lasso di tempo: Day 30, 90 and 180
Social role function is one's ability to perform usual social roles and activities (e.g.: leisure, family). It will be measured by using the APS-SF8. Each item is scored using a 5-point Likert scale (1=Never, 5=Always). Scores are typically converted to a standardized T-score, with a mean of 50 and a standard deviation of 10.
Day 30, 90 and 180
Partners at Care Transitions Measure (PACT-M) - Patient Satisfaction Score
Lasso di tempo: Day 7
Patient satisfaction will be measured using the 9-item PACT-M-1. Scores will range from 9 to 45. Higher scores indicate better perception of the quality of discharge arrangements.
Day 7
Partners at Care Transitions Measure (PACT-M) - Patient Self-Efficacy Score
Lasso di tempo: Day 30
Patient self-efficacy will be measured using the 8-item PACT-M-2. Scores will range from 8 to 40. Higher scores indicate a better experience with managing care at home.
Day 30
Patient Activation Measures Score
Lasso di tempo: Day 60
Patient activation will be measured using the 13-item Patient Activation Measures. Scores will range from 0 to 100. Higher scores indicate greater knowledge, skills, and confidence for managing their health and health care.
Day 60
Preparedness for Caregiving Scale Score
Lasso di tempo: Day 7
Family caregiver preparedness will be measured using the 8-item Preparedness for Caregiving Scale. Scores will range from 0 to 32. Higher scores indicate better preparedness for the caregiving role.
Day 7
Caregiver Self-Efficacy Scale Score
Lasso di tempo: Day 30
Family caregiver self-efficacy will be measured using the 8-item Caregiver Self-Efficacy Scale. Scores will range from 8 to 80. Higher scores indicate higher self-efficacy.
Day 30
Caregiver Activation Measures Score
Lasso di tempo: Day 60
Patient activation will be measured using the 13-item Caregiver Activation Measures. Scores will range from 0 to 100. Higher scores indicate greater knowledge, skills, and confidence for managing their health and health care.
Day 60
Visit Completion Rate
Lasso di tempo: Day 14 and 30
Number of patients that completed follow-up visit
Day 14 and 30
Time to First Outpatient Follow-up
Lasso di tempo: Day 14 and 30
Number of days between discharge and first outpatient follow-up visit
Day 14 and 30
Rate of Access to Community Services - Patient
Lasso di tempo: Day 30 and 60
Number of patients that had screening and intervention assessment for unmet social needs.
Day 30 and 60
Rate of Access to Community Services - Caregiver
Lasso di tempo: Day 30 and 60
Number of caregivers that had screening and intervention assessment for unmet social needs
Day 30 and 60
Partners at Care Transitions Measures - Adverse Events Score
Lasso di tempo: Day 7 and 30
Adverse events will be measured using the 7-item Partners at Care Transitions Measures. Scores will range from 7 to 30. Higher scores indicate greater care problems and more adverse events post discharge.
Day 7 and 30
Mortality Rate
Lasso di tempo: Day 60 and 180
Count of days to date of patient death
Day 60 and 180
Montreal Cognitive Assessment 5-minute Protocol Score
Lasso di tempo: Day 0, 60, and 180
Cognitive function (attention, orientation, language, memory, and executive function) will be measured using the Montreal Cognitive Assessment 5-min protocol. Scores will range from 0 to 30. Higher scores indicate better cognitive function.
Day 0, 60, and 180

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Wake Forest University Health Sciences

Collaboratori

Patient-Centered Outcomes Research Institute

Investigatori

  • Investigatore principale: Thomas Houston, MD, Wake Forest University Health Sciences

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 luglio 2026

Completamento primario (Stimato)

1 novembre 2031

Completamento dello studio (Stimato)

1 novembre 2031

Date di iscrizione allo studio

Primo inviato

16 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

16 giugno 2026

Primo Inserito (Effettivo)

22 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 giugno 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • IRB00145199
  • PLACER-2025C1-43844 (Altro numero di sovvenzione/finanziamento: Patient Centered Outcomes Research Institute)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Transizione di cura

Prove cliniche su Patient-Centered Intervention

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Cameroon

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi